NuGEN Releases Application Note Detailing Lab Study Results of Ovation Biotin System
News Apr 27, 2006
NuGEN Technologies Inc. has announced the release of an application note detailing results of a U.S.-government lab study in which NuGEN's Ovation Biotin system provided increased speed to results and higher specificity of hybridization on GeneChip® probe arrays starting with as little as 50 nanograms of human whole blood total RNA.
The study demonstrated the Ovation system yielded a significantly higher percentage of genes called present.
Since the Ovation system generates cDNA rather than cRNA, hybridization to the DNA content on the Affymetrix GeneChip array results in greater specificity.
The Ovation system is designed to enable researchers to amplify RNA from whole blood and hybridize the target without the need for globin reduction.
"RNA amplification is a common and necessary step when preparing samples for differential gene expression analysis. Researchers must be able to work with a variety of sample types, especially for clinical applications," said Dr. Nurith Kurn, Chief Scientific Officer of NuGEN Technologies.
"The Ovation system allows researchers to obtain highly sensitive and specific gene expression data from whole blood samples with the least amount of sample handling steps, and requires minute amounts of total RNA purified from whole blood samples."
"The study showed that cDNA produced with Ovation and hybridized on the Affymetrix GeneChip afforded significant reduction of cross-hybridization than is typically seen with the standard RNA-to-DNA hybridization process."
"Eliminating the need for globin reduction means that more of the sample is conserved and available for interrogation, providing a higher true gene expression detection rate."
The Ovation Biotin RNA Amplification and Labeling System is designed to provide a protocol for preparing amplified, biotin-labeled cDNA from total RNA for gene expression analysis.
The product of the Ovation Biotin system is optimized for use on Affymetrix GeneChip® arrays. The product can also be used directly in qPCR analysis.
The Ovation Biotin system provides all reagents for first and second strand cDNA analysis, Ribo-SPIA™ amplification, and Fragmentation and Labeling to process 12 (cat. #2300-12) or 60 (cat. #2300-60) or 100 (cat. #2300-100) RNA samples.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.